B. Metzler seel. Sohn & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.09M | Hold |
30,038
| – | – | 0.01% | 521 |
|
|
2025
Q1 | $1.09M | Buy |
30,038
+14,581
| +94% | +$528K | 0.01% | 502 |
|
|
2024
Q4 | $650K | Sell |
15,457
-8,360
| -35% | -$352K | 0.01% | 613 |
|
|
2024
Q3 | $1.32M | Hold |
23,817
| – | – | 0.01% | 491 |
|
|
2024
Q2 | $979K | Hold |
23,817
| – | – | 0.01% | 527 |
|
|
2024
Q1 | $1.11M | Hold |
23,817
| – | – | 0.01% | 505 |
|
|
2023
Q4 | $1.14M | Buy |
23,817
+2,737
| +13% | +$131K | 0.01% | 478 |
|
|
2023
Q3 | $752K | Sell |
21,080
-18,414
| -47% | -$656K | 0.01% | 520 |
|
|
2023
Q2 | $1.82M | Buy |
39,494
+21,158
| +115% | +$976K | 0.02% | 387 |
|
|
2023
Q1 | $735K | Buy |
18,336
+1,741
| +10% | +$69.8K | 0.01% | 494 |
|
|
2022
Q4 | $769K | Buy |
16,595
+7,872
| +90% | +$365K | 0.01% | 480 |
|
|
2022
Q3 | $361K | Sell |
8,723
-406
| -4% | -$16.8K | 0.01% | 596 |
|
|
2022
Q2 | $545K | Sell |
9,129
-336
| -4% | -$20.1K | 0.01% | 542 |
|
|
2022
Q1 | $687K | Buy |
+9,465
| New | +$687K | 0.01% | 546 |
|